XTX Topco Ltd bought a new stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 52,344 shares of the biotechnology company's stock, valued at approximately $562,000. XTX Topco Ltd owned 0.06% of Anavex Life Sciences at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in AVXL. PVG Asset Management Corp purchased a new position in shares of Anavex Life Sciences during the third quarter worth about $74,000. Berkshire Money Management Inc. acquired a new stake in shares of Anavex Life Sciences in the fourth quarter valued at approximately $107,000. Prudential Financial Inc. purchased a new position in shares of Anavex Life Sciences during the fourth quarter worth approximately $109,000. Fiduciary Alliance LLC acquired a new position in shares of Anavex Life Sciences in the 4th quarter valued at $119,000. Finally, D.A. Davidson & CO. acquired a new stake in Anavex Life Sciences during the 4th quarter worth $122,000. Institutional investors and hedge funds own 31.55% of the company's stock.
Anavex Life Sciences Price Performance
Shares of NASDAQ AVXL traded up $0.14 on Thursday, hitting $9.45. The company's stock had a trading volume of 472,035 shares, compared to its average volume of 1,239,111. The stock has a 50 day moving average of $8.76 and a 200-day moving average of $8.69. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44. The company has a market capitalization of $803.85 million, a price-to-earnings ratio of -17.18 and a beta of 0.80.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. Sell-side analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the stock. D. Boral Capital reiterated a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. HC Wainwright reiterated a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Monday, April 7th.
Read Our Latest Report on AVXL
Anavex Life Sciences Company Profile
(
Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
